Allergan Biocell textured breast implant lawsuit MDL 2921: where the BIA-ALCL lymphoma litigation actually stands as bellwethers approach

The Allergan Biocell textured breast implant litigation represents one of the more procedurally complex active medical device mass torts due to its bifurcated MDL structure addressing both cancer and non-cancer injury claims. MDL 2921 (In re: Allergan Biocell Textured Breast Implant Products Liability Litigation), centralized in the U.S. District Court for the District of New Jersey before Judge Brian R. Martinotti and Magistrate Judge Joseph A. Dickson, consolidates approximately 1,481 federal cases as of early 2026. The defendants are Allergan plc and its parent company AbbVie (which acquired Allergan in May 2020), along with Allergan subsidiaries Inamed and McGhan that manufactured some of the recalled devices.

The theory centers on breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a rare but serious cancer of the immune system that the World Health Organization has classified as a CD30-positive, ALK-negative T-cell lymphoma arising in the fibrous capsule surrounding breast implants rather than in breast tissue itself. The FDA first identified a possible association between breast implants and anaplastic large cell lymphoma in 2011 and refined its assessment in March 2018, estimating a lifetime risk between approximately 1 in 3,817 and 1 in 30,000. The critical fact for the Allergan litigation is that approximately 84% of worldwide BIA-ALCL cases have involved Allergan textured implants, with research showing an estimated sixfold higher BIA-ALCL risk for Biocell products compared to other textured implants.

The procedural posture has been affected by the federal preemption defense. As Class III medical devices subject to FDA's Premarket Approval (PMA) process, breast implants fall under Riegel v. Medtronic, Inc., 552 U.S. 312 (2008), which held that the Medical Device Amendments to the Food, Drug, and Cosmetic Act preempt state law tort claims that impose requirements different from or in addition to those imposed by federal law for Class III PMA-approved devices. Allergan has aggressively pursued preemption defenses arguing that plaintiffs' claims challenge manufacturing processes and procedures the FDA has exclusive authority to review. Plaintiffs counter that their claims are based on Allergan's failure to comply with FDA-imposed PMA requirements rather than imposing additional requirements, an approach that survives Riegel preemption under subsequent case law.

This is the science behind the BIA-ALCL theory, the procedural history of MDL 2921 through the bifurcated track structure, the eligibility framework for current and prospective plaintiffs, the bellwether trial schedule, and the strategic considerations for affected patients navigating the complex preemption issues and bifurcated procedural framework.

What are Allergan Biocell textured breast implants and what is the alleged defect?

Allergan Biocell textured breast implants used an aggressive salt-loss texturing process that created larger pores and higher surface area than other textured implants. The alleged defect is that this texturing promotes chronic inflammation and bacterial biofilm formation, leading to BIA-ALCL, a rare T-cell lymphoma. Allergan recalled all Biocell products worldwide in July 2019.

Breast implants come in two main surface types:

Smooth implants. Have smooth surfaces with no texture. Standard since the early days of breast implantation.

Textured implants. Have textured/rough surfaces designed to:

• Reduce capsular contracture (scar tissue squeezing the implant)
• Help the implant stay in position
• Provide more realistic shape for anatomical implants
• Allow tissue to adhere to the implant surface

Textured implants represented a small fraction of overall breast implant usage in the U.S. compared to other countries where textured implants were more common.

The Biocell texturing process. Allergan's Biocell implants used a specific salt-loss process to create the textured surface:

• More aggressive texturing than other textured implants
• Created larger pores in the silicone surface
• Higher surface area than other texturing methods
• Theoretical theory was better tissue integration

The BIA-ALCL mechanism. The current scientific understanding (still developing):

• Texturing creates inflammation in surrounding tissue
• Bacterial biofilm formation on textured surface
• Chronic inflammation causes immune system response
• T-cells in the area undergo malignant transformation
• BIA-ALCL develops in the fibrous capsule
• Cancer can spread if not detected and treated

Specific recalled products. The July 2019 worldwide recall included:

• Saline implants: Natrelle Saline-Filled Breast Implants styles 168, 363, 468
• Silicone 410 series: Natrelle and McGhan Silicone-Filled Breast Implants 410 styles (LL, LM, LF, LX, ML, MM, MF, MX, FL, FM, FF, FX)
• 410 Soft Touch series: Soft Touch styles in same configurations
• INSPIRA series: Natrelle INSPIRA Breast Implants (TRL, TRLP, TRM, TRF, TRX, TSL, TSLP, TSM, TSF, TSX, TCL, TCLP, TCM, TCF, TCX)
• Tissue expanders: Style 133 Biospan Tissue Expander and similar products

Internal corporate knowledge. Discovery has produced internal Allergan documents about Biocell risks:

• Knowledge of disproportionate BIA-ALCL reports from Biocell products
• Awareness of international regulatory actions before U.S. action

What injuries are alleged in the Allergan Biocell breast implant lawsuit?

The cancer track involves BIA-ALCL (breast implant-associated anaplastic large cell lymphoma), a CD30-positive, ALK-negative T-cell lymphoma requiring surgery and sometimes chemotherapy. The non-cancer track covers systemic symptoms, capsular contracture, implant rupture, and breast implant illness. Prophylactic removal cases seek costs of explant surgery.

Plaintiffs in MDL 2921 allege various injuries on two distinct tracks:

Cancer track: BIA-ALCL

• Persistent swelling around breast implant

• Pain in breast or implant area

• Lumps in breast or armpit

• Fluid collection (seroma) around implant

• Skin changes around implant area

• Cytology of fluid collection (seroma fluid analysis)

• Imaging studies (MRI, CT, PET)

• Surgical removal of implant and surrounding scar capsule (en bloc capsulectomy)

• If cancer hasn't spread: surgery alone often curative

• If spread: chemotherapy and possibly radiation

• Treatment costs typically $10,000-$50,000+ for surgery, $100,000-$300,000+ for advanced disease

• Some cases prove fatal, FDA has attributed 12+ deaths to Allergan Biocell

• Need for ongoing cancer surveillance

• Psychological impact of cancer diagnosis

Non-cancer track: Systemic injuries

Approximately 350 non-BIA-ALCL cases in the MDL involve allegations of:

• Chronic systemic symptoms ("breast implant illness")
• Capsular contracture and revision surgery needs

The non-cancer track operates under different evidentiary standards and procedural framework than the BIA-ALCL track, reflecting the different scientific and legal issues involved.

Some plaintiffs received Allergan Biocell implants and had them removed prophylactically due to:

• Cost of removal/revision surgery
• Pain and suffering from additional surgery
• Allergan's "warranty" only covered free replacement with smooth implants, not removal costs

What is the procedural history of MDL 2921?

MDL 2921 was established in December 2019 in the District of New Jersey following Allergan's July 2019 worldwide recall. The litigation uses a bifurcated track structure separating cancer (BIA-ALCL) and non-cancer claims. The first bellwether trial is scheduled for June 15, 2026, with five additional trials extending into 2027.

May 10, 2000. FDA approved Biocell textured breast implants for U.S. market.

June 2011. FDA first identified possible association between breast implants and anaplastic large cell lymphoma.

March 2018. FDA refined assessment and acknowledged measurable lifetime risk associated with textured implants. Cited 1 in 3,817 to 1 in 30,000 risk estimates.

December 2018. Sales of Allergan textured breast implants suspended throughout European Union, Australia, Israel, and Brazil.

May 28, 2019. Health Canada suspended Allergan's Biocell licenses. International regulators acted nearly two months before FDA.

July 24, 2019. FDA requested Allergan voluntary recall of Natrelle Biocell textured breast implants and tissue expanders.

December 18, 2019. Judicial Panel on Multidistrict Litigation established MDL 2921 in the District of New Jersey.

2020-2023. Active discovery, motion practice, and case management. Bifurcated track structure established separating cancer and non-cancer claims.

2024. Master Long Form Personal Injury Complaint filed for BIA-ALCL track.

2025. Allergan filed motion to dismiss based on preemption, citing Illinois state court precedent. Mediation sessions in November 13, 2025 and December 8, 2025.

October 10, 2025. Case Management Order No. 36 addressed approximately 350 cases not involving BIA-ALCL or explant/revision surgery. Separate procedural track for these systemic injury cases.

Late 2025. Case Management Order No. 37 set bellwether trial schedule.

February 6, 2026. Fact discovery deadline for first six bellwether cases.

June 15, 2026.FIRST BELLWETHER TRIAL SCHEDULED. Specific case to be selected from bellwether pool.

Five additional bellwether trials scheduled through subsequent dates extending into 2027.

• BIA-ALCL track has its own expert discovery and procedural framework
• Non-cancer systemic injury track operates separately with different evidentiary standards
• Discovery scope, motion practice, and case development differ between tracks

How does the federal preemption defense affect Allergan Biocell claims?

Federal preemption under Riegel v. Medtronic (2008) shields PMA-approved Class III devices from state tort claims imposing requirements beyond FDA standards. Plaintiffs counter with "parallel claims" alleging Allergan violated existing FDA requirements, including post-market surveillance and adverse event reporting obligations, which survive Riegel preemption.

Medical Device Amendments preemption. Under 21 U.S.C. §360k, the Medical Device Amendments to the Food, Drug, and Cosmetic Act preempt state law requirements that are "different from, or in addition to" any FDA requirement applicable to the device.

Riegel v. Medtronic (2008). Supreme Court held that PMA-approved Class III medical devices receive preemption protection. State law product liability claims that would impose additional or different requirements are preempted.

Plaintiff workaround: parallel claims. Subsequent case law has allowed "parallel claims" that don't impose different requirements but enforce existing FDA requirements:

• Claims based on manufacturer's failure to comply with FDA-imposed PMA conditions
• Claims based on FDA's specific requirements that manufacturer violated
• Adverse event reporting compliance failures

Allergan's defense. Allergan argues that plaintiffs' claims challenge:

If accepted, this argument would preempt most state law tort claims.

Plaintiffs' response. Plaintiffs argue their claims are based on:

• Allergan's failure to comply with FDA-imposed post-market surveillance requirements
• Allergan's adverse event reporting failures
• Allergan's failure to update FDA on emerging risks
• Manufacturing process deviations from FDA-approved specifications

These claims, if properly framed, survive Riegel preemption under subsequent case law.

State court precedent (Illinois). Allergan has cited an Illinois state court decision dismissing claims on preemption grounds. The federal MDL may follow or distinguish this precedent.

Critical issue going into bellwethers. The preemption ruling will substantially affect the litigation's trajectory. Limited preemption application would allow case theories to proceed.

Who is eligible to file an Allergan Biocell breast implant claim?

Eligibility requires documented receipt of an Allergan Biocell textured breast implant. BIA-ALCL track claimants need a confirmed CD30-positive, ALK-negative lymphoma diagnosis with treatment records. Non-cancer track claimants need documented systemic injuries. Prophylactic removal claimants need evidence of explant surgery and costs. Statutes of limitations vary by state, typically 2 to 4 years with discovery rule extensions.

Documented Biocell implant. Records showing the claimant received an Allergan Biocell textured breast implant:

• Operative report from implantation surgery
• Implant card (if provided to patient)
• Hospital records identifying the specific Allergan product (specific style and lot number)

Patient identification. Some patients don't know whether their implants are textured or smooth, or whether they're Biocell or different products.

• Pathology confirming CD30+, ALK- T-cell lymphoma

• Documentation of textured implant association

• Treatment records (surgery, chemotherapy, radiation as applicable)

• Damages (medical expenses, lost wages, quality of life impact)

• Some BIA-ALCL cases have proven fatal. Wrongful death claims for surviving family

• Clinical symptoms consistent with breast implant illness

• Symptom improvement after explant (where applicable)

Statute of limitations analysis. Most states have 2-4 year limitations periods. The discovery rule applies: limitations begins when patient knew or should have known about the connection to Allergan implants. Cases involving recent BIA-ALCL diagnosis or recent symptom development may qualify for discovery rule extension even with older implantation dates.

How does the Allergan Biocell litigation compare to other medical device mass torts?

The Allergan Biocell litigation is distinguished from other medical device mass torts by its bifurcated MDL track structure, PMA preemption defense under Riegel v. Medtronic, and AbbVie's significant financial capacity. Unlike 510(k)-cleared devices in other MDLs, Allergan's PMA approval creates a higher preemption barrier that plaintiffs must overcome through parallel claim theories.

• Bifurcated MDL track for cancer vs. non-cancer injuries
• AbbVie parent company financial capacity
• International regulatory action preceding U.S. action
• 84% of worldwide BIA-ALCL cases involved Allergan products
• Worldwide recall of product line
• Specific cancer (BIA-ALCL) with relatively clear diagnostic criteria

The broader procedural framework for mass tort settlements is detailed in our overview of how mass tort litigation works. Allergan represents medical device mass tort with preemption considerations and bifurcated procedural framework.

What are the projected settlement amounts in the Allergan Biocell lawsuit?

BIA-ALCL cancer cases range from $150,000 to $500,000 for mild cases up to $1 million to $10 million or more for wrongful death. Non-cancer systemic injury cases range from $25,000 to $1 million. Prophylactic removal cases may settle for $25,000 to $100,000.

• Strong scientific basis for causation

• Mild cases (surgery only, full recovery): $150,000-$500,000

• Moderate cases (surgery + chemo, recovery): $500,000-$1,500,000

• Severe cases (advanced disease, permanent impact): $1,500,000-$5,000,000+

• Wrongful death cases: $1,000,000-$10,000,000+

• Mild cases: $25,000-$100,000

• Moderate cases: $100,000-$300,000

• Severe cases: $300,000-$1,000,000+

• Limited damages (cost of explant)

• May be addressed through warranty program

• Settlement ranges: $25,000-$100,000

Tax implications. Personal injury settlements for physical injuries are generally tax-free under IRC §104(a)(2). Coordination with tax counsel is appropriate for settlements, particularly when other tax debt issues or Voluntary Disclosure Practice considerations exist.

AbbVie financial capacity. AbbVie's financial position (over $50 billion annual revenue) provides capacity for global settlement framework. Final settlement timing depends on bellwether outcomes and preemption ruling.

What should Allergan Biocell plaintiffs consider strategically?

Affected patients should identify their specific implant through medical records, pursue BIA-ALCL surveillance with healthcare providers, document the full medical timeline, and engage experienced mass tort counsel. The June 2026 bellwether trial and preemption ruling will shape the litigation's trajectory. Patients should not accept Allergan's limited warranty as sole compensation.

• Check medical records for implant identification
• Contact original surgeon for records
• Hospital may have records identifying specific product
• Recall notification letters confirm Biocell status

Consider BIA-ALCL surveillance. Even without symptoms, patients with Allergan Biocell implants should:

• Monitor for symptoms (swelling, pain, lumps)

• Maintain awareness of recurrence possibility if previously treated

• Pursue specific diagnostic testing if BIA-ALCL suspected

• Don't delay treatment for legal considerations

Document the medical timeline comprehensively. The strongest cases include:

• Allergan product identification (style and lot number)
• Complete medical records from implantation through current
• Diagnosis documentation if BIA-ALCL or other injury
• Treatment records (surgery, chemotherapy, radiation)

Engage experienced mass tort counsel. The MDL is procedurally complex with preemption issues. Counsel with established Allergan case experience handles these cases substantially better. Most firms work on contingency basis (typically 30-40% of recovery).

Address the preemption issue. The pending preemption ruling will substantially affect:

Choose track appropriately. BIA-ALCL track and non-cancer track have different procedural frameworks. Counsel should identify which track is appropriate for your specific case.

Consider state court alternatives. Some plaintiffs may benefit from New Jersey state court filings rather than MDL participation. The procedural analysis depends on specific case facts.

Don't accept inadequate Allergan warranty alone. Allergan's "warranty" provides free implant replacement but doesn't compensate for:

The warranty is inadequate for affected patients with damages.

Coordinate with treating oncologists and surgeons. Plastic surgeons (original implantation), oncologists (BIA-ALCL diagnosis and treatment), and other treating physicians are important witnesses. Their support for the case theory strengthens cases.

Watch for wrongful death framework. Some BIA-ALCL plaintiffs have died from the cancer. Estates can pursue wrongful death claims with separate procedural framework.

Address tax planning for settlements. Personal injury settlements for physical injuries are tax-free under §104(a)(2). Specific component allocation (physical injury vs. emotional distress vs. punitive) affects tax treatment.

Plan for medical monitoring needs. BIA-ALCL surveillance is ongoing for patients with current or former Biocell implants. Even after settlement, medical monitoring may continue for years.

Consider both filing in MDL and explant decision. Some patients defer explant decision pending legal/medical evaluation.

Don't delay claims unnecessarily. Statute of limitations periods are running. Discovery rule provides some flexibility, but cases involving older implantations and recent diagnoses benefit from prompt evaluation.

The Allergan Biocell textured breast implant litigation represents one of the more complex active medical device mass torts due to the combination of bifurcated MDL structure, PMA preemption issues, and the relatively rare but serious BIA-ALCL cancer at the center of the litigation. The case theory has scientific support: FDA acknowledgment of risk, international regulatory actions preceding U.S. action, 84% of worldwide BIA-ALCL cases involving Allergan products, and internal corporate knowledge documented through discovery. The preemption defense is substantial but plaintiffs have plausible parallel claim theories that should survive preemption challenges. The June 2026 bellwether trial start and subsequent trials through 2027 will determine settlement framework. For affected patients with documented Biocell implants and injuries (especially BIA-ALCL diagnoses), the framework provides paths to meaningful compensation that should produce outcomes once procedural complications resolve and bellwether trials provide settlement leverage. The work for plaintiffs is in comprehensive medical documentation including specific implant identification, engagement with experienced counsel familiar with both MDL practice and PMA preemption issues, careful coordination of medical and legal timelines, patient navigation of the bifurcated track structure, and informed monitoring of bellwether and preemption ruling developments.